We’re finally getting a glimpse into what to expect from edoxaban, the 4th new anticoagulant medication.
At the European Society of Cardiology in Amsterdam, it was reported that edoxaban was safer–in other words, had less bleeding–than warfarin for those with deep vein thrombosis (blood clots in the legs) or pulmonary embolism (blood clots in the lungs).
Edoxaban is a Factor Xa inhibitor, similar to rivaroxaban and apixaban, and is taken once daily. In this trial, edoxaban worked best in higher-risk patients.
Results of edoxaban for those with atrial fibrillation should be reported at the upcoming American Heart Association Scientific Sessions in November.